Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Hepatic Cancer: early-phase trial registry

2 of 7 indexed Hepatic Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 2 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Hepatic Cancer: 7 US clinical trials tracked, 2 recruiting.

Hepatic Cancer is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is H3 Biomedicine, running 1 of these trials.

Enrollment posture brief

Registry condition hepatic-cancer

OPEN 2 | RECR 29% | LATE 0 | EARLY 3 | RANK #2497 | SPON 1

Nearest open-share peer: Acromegaly (29% recruiting · 14 trials)

ACL Tear71.4%ACL57.1%Acute Myelogenous Leukemia42.9%Hepatic Cancer (this)29%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Hepatic Cancer

Hepatic Cancer lists 2 open slots (29% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hepatic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hepatic Cancer is recruiting below its size-band peers.

    2 of 7 indexed trials (28.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Hepatic Cancer trials is spread across many organizations.

    H3 Biomedicine accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Typical Hepatic Cancer enrolment sits around 107 participants.

    Median target enrolment is 107 among the 7 trials that report a genuine target (sentinel values excluded). 3 of those (42.9%) plan for fewer than 100 participants.

  4. Hepatic Cancer research is mostly interventional.

    6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 21

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1

Named interventions

Most-linked intervention names on Hepatic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

CS-1008 4 mg/kg Drug
1 trials
CS-1008 6/6 mg/kg Drug
1 trials
CS-1008 6/2 mg/kg Drug
1 trials
CS-1008 2 mg/kg Drug
1 trials
Recombinant Human Thrombopoietin Drug
1 trials
Ablation Probe Procedure
1 trials
CT/CBCT thermometry method Procedure
1 trials
H3B-6527 Drug
1 trials

US sites by state

Facility locations filed on Hepatic Cancer trials. A trial with sites in several states counts in each.

California 3 trials
Tennessee 2 trials
Pennsylvania 2 trials
New York 2 trials
Virginia 1 trials
Texas 1 trials
Ohio 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hepatic Cancer page

7 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Hepatic Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • H3 Biomedicine sponsors the most Hepatic Cancer trials on record, review their full trial history before evaluating a specific study. See H3 Biomedicine's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatic Cancer condition card totals 7 registered trials; most-linked intervention CS-1008 4 mg/kg; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.